---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-043416"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2026-06-16T11:34:21+00:00"
generated_at: "2026-06-16T11:35:15.747119+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acumen nominates two EBD Alzheimer's candidates (ACU301, ACU401); IND in mid-2027

## Summary
- Nominated ACU301 (bispecific from sabirnetug) and ACU401 (novel AβO-selective antibody ACU234).
- Exercised option under JCR collaboration; combines Acumen's AβO antibody with J-Brain Cargo BBB-penetrating tech.
- Preclinical data: 14-40x higher brain penetration in NHPs vs native antibodies; low anemia risk; no adverse events.
- IND-enabling activities ongoing; IND submission targeted mid-2027; SC dosing suitability demonstrated.

## SEC filing metadata
- accession: 0001628280-26-043416
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2026-06-16T11:34:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000162828026043416/0001628280-26-043416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000162828026043416/abos-20260612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-043416
- JSON: https://secwatch.observer/filing/0001628280-26-043416.json
- Plain text: https://secwatch.observer/filing/0001628280-26-043416.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.